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Background: Interleukin-24(IL-24), also referred to as melanoma differentiation-associated gene-7(mda-7), is a unique
member of the IL-10 gene family, which displays nearly ubiquitous cancer-specific toxicity. The most notable feature of
IL-24 is selectively induced growth suppression and apoptosis in various cancer cells, with no harmful effects
toward normal cells. Autophagy is a self-protective mechanism in many kinds of tumor cells that respond to
anticancer treatment. It is reported that autophagy inhibition could enhance the effects of many kinds of anticancer
treatments, including gene therapy. However, whether IL-24 is effective to treat oral squamous cell carcinomas (OSCC)
and if autophagy inhibition could improve the anticancer effect of IL-24 towards OSCC is has not been detected.
Methods: MTT assays were carried out to determine the cell proliferation; Transfection was used to gene
transfer; Western Blot was performed to detect the protein level of LC3II, P62, Beclin 1, Cleaved caspase-3, β-Tubulin
and β-actin; Apoptosis rates and cell cycle alteration were analyzed using flow cytometry; Autophagy induction was
confirmed by MDC staining, GFP-LC3 staining and transmission electron microscopy. Amount of IL-24 in the culture
medium was quantified by ELISA. Apoptosis in vivo was analyzed by TUNEL assay. HE staining was used to observe the
morphology of the samples.
Results: In the present study, we proved that IL-24 have a novel anticancer effect towards KB cells and that autophagy
inhibition could improve the anticancer effect of IL-24. IL-24 treated cells showed autophagy characteristics
and autophagy inhibition by 3-methyladenine (3-MA) significantly enhanced IL-24-induced apoptosis. Similar
results were obtained in the KB cells xenograft tumor model.
Conclusions: These results suggest that the combination of autophagy inhibitors and IL-24 based on the AdLTR2EF1α-
mediated gene transfer could be a promising way to cure OSCC.
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Oral cancer is a widespread malignant disease, with over
640,000 new cases being found annually worldwide. There
are several types of oral cancers, but approximately than
90 % are squamous cell carcinomas. The prognosis of
OSCC is poor due to their strong invasive nature [1].
While the effect of conventional treatments, such as* Correspondence: hcsun@mail.jlu.edu.cn; liyugene@hit.edu.cn
4Department of Oral Pathology, School of Stomatology, Jilin University, 1500
Qinghua Road, Changchun 130021, People’s Republic of China
1School of Life Science and Technology, Harbin Institute of Technology, 2
Yikuang Street, Harbin 150001, People’s Republic of China
Full list of author information is available at the end of the article
© 2015 Li et al. Open Access This article is di
License (http://creativecommons.org/licenses/
medium, provided you give appropriate credi
Commons license, and indicate if changes we
creativecommons.org/publicdomain/zero/1.0/surgical removal, chemotherapy and radiotherapy is lim-
ited for oral cancer. Recent years, gene therapy known as
a new way of treating cancer have attracted increasing
interest. Gene therapy describes the delivery of a
functional therapeutic gene to target cells, which may
be used to knockdown expression of a particular macro-
molecule, improve the level of desired protein, directly in-
duce cell death, or replace a defective or mutant gene to
allow a normal protein product to a certain level. mda-7/
IL-24 is an unusual member of the IL-10 cytokine family
[2], with ubiquitous tumor cell proapoptotic activity [3].
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when administered by adenovirus [4]. Despite extensive
studies, questions still remain about how to further en-
hance the anti-tumor effect of IL-24.
Recently, the elegant concept of autophagy inhibition
provides a new strategy for efficient cancer therapy. In
general, when the cells respond to the limited nutrition
and growth factors, autophagy is activated and contributes
to maintaining homeostasis through degradation of im-
paired or unnecessary macromolecules and organelles,
thereby providing energy to cancer cells [5]. Autophagy
usually serves as a protective mechanism for tumor cells
exposed to anticancer treatments [6]. In preclinical trials,
repression of autophagy has demonstrated an increased
efficacy of chemotherapeutics, both in vitro and in vivo
[7–10]. Recent studies have shown that IL-24 induces
endoplasmic reticulum stress response via induction of
autophagy in glioblastoma cells through PERK activation
[11]. However, whether autophagy inhibition can enhance
the acticancer effects of IL-24 in treating oral cancer is
have not been investigated.
In this study, we utilized a novel hybrid gene delivery
vector named AdLTR2EF1α-based vector, which we have
constructed in our previous work [12], as a gene carrier of
IL-24 to treat KB(human Oral epidermoid cancer cells)
and HaCaT(immortal human keratinocyte cells) cell lines.
High level of apoptosis as well as autophagy were ob-
served in AdLTR2EF1α-IL-24 treated cells. To our sur-
prise, while the autophagy induced by AdLTR2EF1α-IL-24
was blocked by autophagy inhibitor 3-MA, a significant
increase of anticancer effect was detected. Similar results
were obtained in KB xenografts in nude mice. This work
highlights the potential of combination of IL-24 gene and
autophagy inhibitor for enhanced efficacy against aggres-
sive oral cancer.
Methods
Cell lines and cell cultures
In this study we used KB cells and HaCaT cells (control).
KB cells were cultured in RPMI 1640 medium (Gibco,
USA) and HaCaT cells were cultured in DMEM medium
(Gibco, USA). All medium was supplemented with 10 %
fetal bovine serum (Gibco, USA), and 1 % penicillin and
streptomycin at 37 °C in 5 % CO2, 95 % humidified
incubator.
AdLTR2EF1α-mediated gene transfer
In order to assess the appropriate transfection concentra-
tion, KB and HaCaT cells were infected with AdLTR2EF1α-
vec, at different concentrations. Cell viability was assessed
by MTT 72 h after infection. After determining the optimal
transfection concentration, KB cells and HaCaT cells were
infected with AdLTR2EF1α-EGFP at 1000 pfu/cell. En-
hanced level of green fluorescent protein (EGFP) wasexamined by fluorescence microscopy at 12, 24 and
48 h after infection. Expression of transgenic IL-24 in
KB and HaCaT cells was determined by real time reverse-
transcription polymerase chain reaction (real time RT-
PCR) 48 h after infection. Total RNA was extracted using
RNeasy mini purification kit (Qiagen, USA). RNA was
quantitated using a NanoDrop2000 spectrophotometer
(Thermo, USA). Complementary DNA was synthesized
with reverse transcriptase (TaKaRa, Japan), The qPCRs
were performed using SYBR-Green premix Ex Taq (Takara)
(n = 3) and MxPro Mx3005P real-time PCR detection sys-
tem (Agilent, USA). IL-24 gene was amplified using the
specific primers forward 5′- AAGCCTGTGGACTTTAGC
CAGACC -3′and reverse, 5′- GCACTCGTGATGTTAT
CCTGAGC -3′. β-actin primers forward 5′- TGGCACC
CAGCACAATGAA -3′, and reverse 5′- CTAAGTCA
TAGTCCGCCTAGAAGCA -3′ for human β-actin ampli-
con as internal control. Primers were synthesized commer-
cially (TaKaRa Biotechnology [Dalian] Co). Furthermore,
IL-24 in the culture medium of all samples was quantified
by sandwich enzyme-linked immunosorbent assay (ELISA)
kits (Lengton, China).
Measurement of autophagy
KB cells were infected with AdLTR2EF1α-IL-24 or
AdLTR2EF1α-vec. Before each time point, cells were
cultured with 50 μM Monodansylcadaverine (MDC)
for 1 h, and then trypsinized. Trypsinized cells were col-
lected, resuspended, dropped onto a glass slide and
examined under fluorescence microscopy in UV chan-
nels. Additional cells were transfected with green fluores-
cent protein (GFP)–labeled LC3 fusion protein following
infection with AdLTR2EF1α-IL-24. Cells was examined at
different time points after infection using fluorescence mi-
croscopy. At each time point, cells in each group were col-
lected and washed with cold PBS, then 0.25 % neutral
glutaraldehyde fixed overnight at 4 °C for TEM sectioning.
Subsequently, the cellular microstructure was observed by
the transmission electron microscope (TEM).
Western blotting
KB cells infected with AdLTR2EF1α-IL-24 or AdLTR2EF1α-
vec were cultured at 37 °C for 48 h. Cells were harvested
and resuspended in lysis buffer containing 50 mM Tris–HCl
(pH7.4), 150 mM NaCl, 1 % Triton X-100, 1 % sodium
deoxycholate, 0.1 % SDS and 1 % protease inhibitor cocktail.
Protein from each sample was separated by SDS-PAGE and
PVDF membranes. The membranes were blocked with 5 %
skim milk, primary antibodies diluted with TBS-T by 1:1000
and incubated with primary antibody at 4 °C for 12 h,
followed by incubation with secondary antibody diluted with
TBS-T for 1 h. LC3-II antibody purchased from Abcam
company (USA). The protein levels of LC3-II were
detected by Odyssey Two-Color Infrared Imaging System
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cence). β-tubulin was used as a loading control. IL-24,
cleaved caspase-3, Beclin-1 and P62 antibody purchased
from ProteinTech Group (UK). The protein levels of
cleaved caspase-3, Beclin-1 and P62 were detected by en-
hanced chemiluminescence (ECL). β-actin was used as a
loading control .
Apoptosis analyses with flow cytometry
Apoptosis was analyzed by flow cytometry, using annexin-
V and PI double staining following the manufacturer’s pro-
tocol(Invitrogen, USA). Briefly, OSCC cells and control
cells were cultured either with or without 3 mmol/L 3-MA
and with either AdLTR2EF1α-IL-24, AdLTR2EF1α-vec or
virus dilution buffer. Two days later, cells were collected
and washed with cold PBS and annexin-binding buf-
fer. Then, annexin V and PI working solution were added
cell suspension, then incubated at room temperature for
15 min. After the incubation period, the stained cells were
analyzed with flow cytometry.
Measurement of caspase activity
Caspase activity was measured using Caspase-Glo 3/7
assay kits (Promega, USA). Cells in each group were plated
in opaque 96-well plates in triplicate. After 48 h, the assay
reagents were added to the plates at room temperature
and incubated for 60 min, and the fluorescence from the
plates was then measured on a plate reader at 490 nm (ex-
citation) and 510–570 nm (emission). Values were normal-
ized to percentage of untreated control groups.
In vitro cytotoxicity studies
KB and HaCaTcells were treated with various AdLTR2EF1α-
based viruses (with or without 3-MA). Cells were incubated
with 50 μl of MTT solution (5 mg/ml) for 4 h at 37 °C
at the indicated time points after treatment. After incu-
bation, medium was removed in each well and replaced
with 100 μl Dimethyl sulfoxide (DMSO), then mixed thor-
oughly. Absorbance from the plates was read on a micro-
plate reader at 490 nm wavelengths. The percentage of
cell viability was calculated by multiplying the ratio ab-
sorbance of the sample versus the control by 100.
Cell cycle alteration
KB and HaCaT cells were cultured in 6-well plates after
transfection. After 48 h, cells were harvested by trypsiniza-
tion, washed in cold PBS, fixed with 70 % ethanol at −4 °C
for 4 h, and then were stained with propidium iodide (PI).
DNA contents and cell cycle phases were analyzed using
flow cytometry.
Anticancer effect in vivo
To determine whether the IL-24 gene and 3-MA would
suppress the growth of tumor, twenty male Balb/c-nudemice (4–6 weeks old) were injected with KB cells (1.5 × 106
cells per mouse) in the dorsal flank to create subcutaneous
tumors. When tumor size reached a predetermined size
(50-80 mm3, about 8 days after the injection), mice were
randomly divided into control, 3-MA, IL-24 and combin-
ation groups (n = 5 for each group). AdLTR2EF1α-IL-24
(1010pfu/50ul) was injected around the tumor and 25per
kilogram of 3-MA dissolved in 100ul saline was injected
intraperitoneally every 6 days, a total of 3 times (day 6, 12,
18). As control, the same amount of saline was injected.
Tumors were measured every 2 days and tumor vol-
umes were calculated using the formula V = 1/2ab2 (where
a is the largest diameter and b is the smallest diameter).
Animals were observed for 30 days. After 1 month,
tumor xenografts, hearts, livers and lungs were excised,
routine fixed, paraffin-embedded, sliced and stained with
HE. Terminal deoxynucleotidyl transferase-mediated bio-
tinylate dUTPnick end labeling (TUNEL) assay was per-
formed in the edge region of the tumor by using
TUNEL Apoptosis Assay Kit-FITC according to the
manufacturer’s protocol (7 Sea Biotech). All manipula-
tions involving living mice were approved by the Ani-
mal Care and Use Committee of the Harbin Institute of
Technology.
Statistical analysis
Results are expressed as mean ± SD. Statistical analysis
was performed using the one-way analysis of variance
and multiple comparison method, with P < 0.05 deemed
as statistically significant. All experiments were repeated
at least three times.
Results
Cytotoxicity and expression of the transgene
As shown in Fig. 1a, at concentrations 250 to 1500pfu/
cell, cell viability of KB and HaCaT cells had no differ-
ence compared with the vector-free control group. In
2000 pfu/cell group and 2500 pfu/cell group, there was a
slight decrease in cell viability compared with the vector-
free control group. Therefore, we selected 1000 pfu/cell as
the appropriate concentration of AdLTR2EF1α-based vec-
tor with which to infect KB cells and HaCaT cells in sub-
sequent experiments. As shown in Fig. 1b, more than
90 % of EGFP expression was found in KB cells when in-
fected with AdLTR2EF1α-EGFP. While in HaCaT cells
EGFP expression level was about 15 %. The transgenic ex-
pression was determined by real time RT-PCR. As shown
in Fig. 1c and d, a significant amount of IL-24 transcrip-
tional expression was found in the AdLTR2EF1α-IL-24
treated KB and HaCaT cells, but IL-24 expression in the
AdLTR2EF1α-vec treated and untreated groups was low.
Furthermore, cells were infected, and then analyzed with
Elisa Assay. As shown in Fig. 1e, We found the medium
background was 361.33 ng/L in RPMI 1640 medium and
Fig. 1 a Three days after infection with AdLTR2EF1α-vec, the cell viability was measured by MTT assay. Values represent mean ± SD (n= 5). b Cells were
infected with AdLTR2EF1α-EGFP at MOI of 1000. The viral replication was monitored under the fluorescence microscope at 12, 24 and 48 h after infection.
c Hybrid vector mediated IL-24 transcriptional expression in KB cells by real time RT-PCR analysis. Values represent mean ± SD (n = 3). d Hybrid vector
mediated IL-24 transcriptional expression in HaCaT cells. Values represent mean ± SD (n = 3). e The IL-24 protein levels in the culture medium of all
samples were determined by ELISA. A significant increase compared with the control is denoted by “***”(P < 0.001). Values represent mean ± SD (n = 3)
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FCS). After subtracting the medium background, the date
show that, IL-24 secretion in AdLTR2EF1α-IL-24 treated
cells was significantly higher than that of the control and
AdLTR2EF1α-vec treated groups.
These results suggest that transgenic IL-24 mediated
by the vector was expressed in KB and HaCaT cells at
both the transcriptional and translational levels.AdLTR2EF1α-IL-24 induces autophagy in human OSCC
cell line
The auto fluorescent drug MDC is a selective marker
for autophagy vacuoles [13]. MDC accumulates in ma-
ture autophagy vacuoles, such as autophagosomes and
autolysosomes. Autophagy was confirmed by MDC-
staining of KB cells. As shown in Fig. 2a, AdLTR2EF1α-
IL-24 treated cells showed an increasement in the number
Fig. 2 a MDC staining for transfected KB cells. b GFP-LC3 staining for transfected KB cells. c TEM images of transfected KB cells. Red arrows indicate
autophagosomes and blue arrows indicate autolysosomes
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dicating that IL-24 induced the formation of the autopha-
gosomes and autolysosomes. The localization of LC3 in
autophagy vacuoles in the IL-24 treated KB cells was de-
termined by transient transfection of a plasmid expressing
green fluorescent protein fused with LC3 (GFP-LC3)
followed by infection. Similar to MDC staining, after in-
fection, GFP-LC3 staining increased in AdLTR2EF1α-IL-24
treated KB cells, when compared with the AdLTR2EF1α-vec treated groups (Fig. 2b). TEM was used to detect au-
tophagy vesicles with double membrane structure, also
called autophagosomes. The existence of these vesicles is
morphological evidence of autophagy. AdLTR2EF1α-IL-24
induced a large number of autophagosomes in KB cells
while the AdLTR2EF1α-vec treated or untreated KB cells
showed low numbers of autophagosomes (Fig. 2c). These
results indicate that AdLTR2EF1α-IL-24 can strongly in-
duce autophagy in KB cells.
Fig. 3 (See legend on next page.)
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Fig. 3 a KB cells were transfected and the level of LC3 was analyzed by Western immunoblotting. Densitometry was performed on the original
blots, and the ratio of LC3-II/β-tubulin in control cells was 1. b Western immunoblotting analysis of P62, Beclin-1, Cleaved caspase-3 and IL-24 in
KB cells. c Semiquantitive analysis of P62, Beclin-1 and Cleaved caspase-3 in Kb cells. Compared with the control group denoted by “*” (p < 0.05).
Compared with the IL-24-treated group denoted by “#” (p < 0.05). Values represent mean ± SD (n = 3)
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To further investigate the autophagy inducing effect of
AdLTR2EF1α-IL-24, cells were treated with different
groups and the autophagy related proteins LC3-II, Beclin-1
and P62 were analyzed. As Fig. 3a shows, Infection of KB
cells with AdLTR2EF1α-IL-24 led to an accumulation of
LC3-II in a time-dependent manner when compared to the
other groups. Moreover, treated KB cells showed an in-
crease of Beclin-1 and decrease of P62 (Fig. 3b and c). Con-
sistence with the results of MDC staining, GFP-LC3
transfection and TEM observation, these data also suggest
that AdLTR2EF1α-IL-24 strongly induce autophagy in KB
cells. Besides, to detect whether AdLTR2EF1α-IL-24 can
lead to apoptosis, cells were treated by different groups and
as a marker of apoptosis, the apoptosis related protein -
cleaved caspase-3 was measured by western blot. As shown
in Fig. 3b and c, the level of cleaved caspase-3 in combin-
ation of AdLTR2EF1α-IL-24 and 3-MA treated group was
significantly up regulated compared to the other ones. This
demonstrates that, AdLTR2EF1α-IL-24 can induce apop-
tosis in KB cells and the autophagy inhibitor 3-MA can en-
hance the apoptosis-inducing effect of AdLTR2EF1α-IL-24.
Moreover, we also examine the level of IL-24 in KB cells
treated with different groups. As Fig. 3b shows that in cells
treated with IL-24 and IL-24 + 3-MA shows a high level of
IL-24 and other groups express a low level of IL-24.
IL-24 induced OSCC apoptosis was enhanced by 3-MA
treatment
As shown in Fig. 4a and b, the treatment of KB cells by
AdLTR2EF1α-IL-24 caused 37.72 % of cells apoptosis in
the late and the early stage, whereas combining
AdLTR2EF1α-IL-24 with 3-MA resulted in 49.72 %
of cells apoptosis in the two stage total. Moreover, in
the control group, the 3-MA group, the induced apoptotic
percentages in KB cells are 16.64 and 18.09 %, respect-
ively. However, in the human keratinocyte HaCaT cells,
there were no apparent difference in all groups. Addition-
ally, caspase-3/7 activities were increased obviously in the
3-MA combining with AdLTR2EF1α-IL-24 group in KB
cells. However, there were no significant changes in
HaCaT cells in all of the groups (Fig. 4c). These results in-
dicate that 3-MA enhance the IL-24 induced apoptosis.
Effects on cell proliferation
As shown in Fig. 5a, the cell viability of the control
group is assumed to be 100 %. In KB cells, there was no
significant retarding effect neither in the 3-MA groupnor in the AdLTR2EF1α-IL-24 group. In AdLTR2EF1α-
IL-24 group, the cell viability of KB cells was decreased
to 69.05 %. However, in AdLTR2EF1α-IL-24 combining
with 3-MA group, cell viability was reduced to 43.37 %.
These data indicate that AdLTR2EF1α-IL-24 combining
with 3-MA treatment inhibit the cell proliferation more
effectively. But in HaCaT cells (Fig. 5b), no significant in-
hibition was observed in the IL-24, 3-MA or IL-24 com-
bining with 3-MA groups (96.45 %, 97.74 and 94.80 %).
In addition, the cell cycles of KB cells (Fig. 5c) show
higher levels of G2-M phase arrest in the IL-24 group
(70.19 %), compared with the control group (25.04 %).
The levels of G2-M phase arrest of the 3-MA group was
similar to the control group (24.9 %). The IL-24 combin-
ing with 3-MA group showed the highest levels of G2-M
arrest (88.85 %). In HaCat cells (Fig. 5d), no significant
difference in G2-M phase arrest was observed among
the control, 3-MA and IL-24 groups (12.29, 12.85 and
15.50 %), and there was slightly higher levels in the
combination group (26.77 %), compared with the con-
trol group (24.9 %). These results demonstrated that
AdLTR2EF1α-IL-24 selectively inhibits cancer cell pro-
liferation by inducing G2-M cell cycle arrest, while there
was no similar effect on normal cells. 3-MA treatment had
no obvious effect on cell proliferation of normal and tumor
cells. But AdLTR2EF1α-IL-24 combining with 3-MA influ-
enced the cell cycle of tumor cells strongly. However, the
cell cycle of normal cells was just affected slightly by it.
Antitumor efficacy of IL-24 combining with 3-MA
To evaluate treatment effect, tumor-bearing mice were di-
vided into four groups: control, 3-MA, IL-24 and IL-24
combining with 3-MA treatment group. All of the nude
mice were healthy and body weight showed no significant
difference in all groups (Fig. 6g).
Tumor volume and body weight of tumor-bearing mice
were monitored every 2 days for 22 days. Compared with
the control group, the tumor growth rate and size of IL-
24-treated group were significantly reduced and IL-24
combining with 3-MA group were further decreased
(Fig. 6e and f). The 3-MA-treated group had no significant
influence on tumor growth rate and size. After 30 days
treatment, the mean tumor weight and mean tumor vol-
umes of the IL-24 combining with 3-MA group were sig-
nificantly reduced by 36.21 and 52.03 %, compared with
the IL-24 group. HE staining of the tumors showed that, in
the control group and 3-MA group, tumor cells grew more
actively, their nuclei stained more deeply, they exhibited
Fig. 4 a KB and HaCaT cells were transfected. Cell apoptosis was measured by the flow cytometry at 48 h after infection. b The ratio of “late”
apoptosis among different experimental groups. c Caspase activity of KB and HaCaT cells. A significant increase compared with the control is
denoted by “***” (P < 0.001) and a significant increase compared with the “without 3-MA group” is denoted by “***#” (P < 0.001). Values
represent mean ± SD (n = 3)
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two groups. However, in the IL-24 group and the com-
bination group tumor cells’ growth was inhibited. How-
ever, there were a large number of necrotic cells, whichhave undergone karorrhexis (fragmentation) and karyoly-
sis (dissolution) forming a uniform pink area, in the IL-24
group and the IL-24 combining with 3-MA group (Fig. 7a).
Immunohistochemistry results showed that,we can found
Fig. 5 a Cell viability of KB cells was measured by MTT assay. Values represent mean ± SD (n = 3). b Cell viability of HaCaT. c Cell cycle phases of KB
cells were analyzed using flow cytometer. d Cell cycle phases of HaCaT cells. A significant decrease compared with the control is denoted
by “***” (P < 0.001) and a significant decrease compared with the “without 3-MA group” is denoted by “***#” (P < 0.001)
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combining with 3-MA treated group. Whereas in the con-
trol group and 3-MA treated group, we found a low level
of IL-24 protein (Fig. 7e and f). Hence, we confirm that
tumor cells’ growth was inhibited in the IL-24 group and
the IL-24 combining with 3-MA group. Besides, there
were no difference in the tissues of heart, liver and lung
by HE staining (Fig. 7b, c and d). Moreover, IL-24 and IL-
24 combining with 3-MA group appeared increased num-
ber of TUNEL-positive cells (FITC-12-dUTP-Lable, green
fluorescence). Whereas DNA fragmentation (measured by
TUNEL assay) was rare in the control group and 3-MA
group (Fig. 7g and h). These results prove that IL-24 has a
strong antitumor effect in vivo and 3-MA improve the an-
titumor effect of it.
Discussion
Carcinomas of the oral cavity, particularly OSCC, have
become an important health care problem worldwide.
The survival rates for oral carcinomas are lower thanthose for most other carcinomas and have not improved
substantially in recent years. The conventional treatment
includes a combination of surgery, radiation therapy, and
chemotherapy. Hence, to find a novel systemic therapy for
OSCC is of great importance. Gene therapy of cancer has
been taken into account as a potential therapeutic method.
Cancer gene therapy can be defined as the use of gen-
etic material to manipulate tumor or normal cells to en-
courage anti-tumor activity such as direct killing of cells,
immunomodulation or correction of genetic errors, and
reversion of malignant status [14]. A successful cancer
gene therapy requires an appropriate gene which dis-
plays selective toxicity toward tumor cells without elicit-
ing harmful effects in normal cells or tissues. As a novel
candidate for cancer gene therapy, IL-24 was cloned
using subtraction hybridization from terminally differen-
tiated human melanoma cells. Its unique properties in-
clude its ability to selectively induce growth suppression
and apoptosis in diverse human cancer cells, without
harmful effects on normal cells. Furthermore, the “potent
Fig. 6 a Removed KB tumor xenografts from the control group. b Xenografts from the 3-MA group. c Xenografts from the IL-24 group. d Xenografts
from the combination group. e Tumor volume of KB xenografts. f Tumor weights of KB xenografts. g Body weights of the mice. Values represent
mean ± SD (n = 5)
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tumor properties of IL-24 [15]. IL-24 secreted by adjacent
tumor or normal cells can induce direct antitumor effect
in tumor cells not initially receiving this gene product.
However, a successful gene therapy also requires an
appropriate kind of vectors. The ideal vectors should en-
sure a high level of transfection and should also main-
tain the gene expression for a suitable period of time
and have no cytotoxicity. The two common viral vectors,
based on adenovirus or retrovirus, have advantages and
drawbacks. Traditional adenovirus has advantages includ-
ing ease of production, high titers, efficient transduction
into many types of cells, and infrequent genomic integra-
tion [16, 17]; But also has the shortcomings of provoking
vigorous immune responses and only providing short-
term transgenic expression (14 days) [18]. The period of
time transgenic expression provided by retrovirus vectors
is longer than that of adenovirus vector, but their trans-
duction requires cell division, and genomic integration
may be uncontrolled, thereby introducing the risk of inser-
tional mutagenesis [19, 20].
The viral vector used in this study is an adenovirus-
retrovirus hybrid vector, named AdLTR2EF1α-base vector.
It can be transfected into a variety of cells, and can provideintermediate-length (1–3 months) expression of the gene,
with low frequency of genomic integration. Tumor cells or
normal cells infected with AdLTR2EF1α-IL-24 inhibit the
surrounding tumor cells, that not initially infected with
AdLTR2EF1α-IL-24, through the “bystander” effect. The
intermediate-length expression ofAdLTR2EF1α-IL-24 is
conducive to exerting the anti-tumor “bystander” effect.
Thus the AdLTR2EF1α-base vector is an ideal vector for
cancer gene therapy.
Our studies demonstrated that AdLTR2EF1α-IL-24 in-
duces not only KB cells but also HaCaT cells to express
IL-24 highly. In KB cells, infection with AdLTR2EF1α-
IL-24 induced a high level of apoptosis, whereas the
AdLTR2EF1α-vec did not have such effects. However, in
HaCaT cells, high level of IL-24 did not lead to obvious
increasement of apoptosis. It indicates that IL-24 only
harmful to tumor cells and almost have no damage to
normal cells. Thus AdLTR2EF1α-IL-24 may become a
new therapeutic agent for cancer gene therapy, given the
intermediate-length expression and targeted induction of
apoptosis.
Autophagy is a catabolic process. Cells employ autophagy
to recycle basic biomolecules during nutrient deprivation,
to scavenge damaged organelles and harmful proteins, and
Fig. 7 a HE staining of tumor xenografts in each group (×40). b HE staining of heart (×200). c HE staining of liver (×100). d HE staining of lungs(×200).
e Immunohistochemical staining of IL-24 in each group (×200). f Local Application of immunohistochemical staining of IL-24 in each group.
g Apoptotic TUNEL assay from tumor xenografts (×400). h Local Application of Apoptotic TUNEL assay from tumor xenografts. FITC-labeled TUNEL-
positive areas represent apoptotic cells
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tophagy plays a crucial role in maintaining cellular homeo-
stasis, and also contributes to cell survival during times of
stress [21]. Although apoptosis and autophagy constitute
different cellular processes and generally cause opposite re-
sults, their signaling pathways are interconnected by a wide
variety of mechanism crosstalk. It is a key factor in death-
related pathologies such as cancer [22]. In cell, such a
crosstalk is synergistic, accomplished by a variety of mecha-
nisms including the ATG5–ATG12 conjugation [23], the
Beclin 1–VPS34 complex [24], as well as caspase-8 and au-
tophagic cargo receptor p62 interaction [25]. In this study,we confirmed that AdLTR2EF1α-IL-24 induced autophagy
of KB cells by MDC staining, GFP-LC3 staining, western
immunoblotting and transmission electron microscope ob-
servation. We consider that autophagy is a self-protection
mechanism against IL-24 induced apoptosis in cancer cells.
Inhibition of autophagy in tumor cells has been reported to
enhance the effect of chemotherapy and to increase the
cytotoxicity induced by drug. One of the most important
effects of cytotoxicity is apoptosis [26]. To identify whether
autophagy inhibition can improve the apoptosis-inducing
effect of IL-24, a well known autophagy inhibitor 3-
MA was introduced. The results from MTT assays, flow
Li et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:97 Page 12 of 13cytometric and caspase-3/7 activity assays demonstrated
that the autophagy inhibitor 3-MA can strongly enhance
the anticancer effect of IL-24.
However, although 3-MA can enhance the antitumor ef-
fect of IL-24 in vitro, whether it is also effective in vivo is
need to be investigated. In this study we established KB
xenografts models and treat the mice with 3-MA, IL-24
and the combination of 3-MA and IL-24. Our data indi-
cate that tumor volume and mass of the IL-24 treated
group was significantly less than that of the 3-MA treated
group and control group, while the combination of 3-MA
and IL-24 group was even less than the IL-24 group. HE
staining and TUNEL experiments further confirmed these
results. Consistent with the results of in vitro experiments,
these data indicate that AdLTR2EF1α-IL-24 not only has
antitumor effects in vitro, but also has similar effects
in vivo, and autophagy inhibition can enhance the antitu-
mor effect of AdLTR2EF1α-IL-24 both in vitro and in vivo.
Conclusion
This study has demonstrated that IL-24 carried by
AdLTR2EF1α vector has a strong anticancer effect towards
OSCC in both in vitro and in vivo experiments. Autoph-
agy, as a self-protective mechanism, was induced by IL-24
treatment and the autophagy inhibition by 3-MA signifi-
cantly enhance the anticancer effect of IL-24. Therefore,
we believe that the strategy of combination of IL-24 and
autophagy inhibitor will open up new perspectives in clin-
ically applicable combination therapy to treat OSCC.
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